Nothing Special   »   [go: up one dir, main page]

CA2255540A1 - Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers - Google Patents

Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Info

Publication number
CA2255540A1
CA2255540A1 CA002255540A CA2255540A CA2255540A1 CA 2255540 A1 CA2255540 A1 CA 2255540A1 CA 002255540 A CA002255540 A CA 002255540A CA 2255540 A CA2255540 A CA 2255540A CA 2255540 A1 CA2255540 A1 CA 2255540A1
Authority
CA
Canada
Prior art keywords
antigen
fragments
antigen binding
binding fragments
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255540A
Other languages
French (fr)
Other versions
CA2255540C (en
Inventor
Michael D. Dan
Howard A. Kaplan
Pradip K. Maiti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1997/008962 external-priority patent/WO1997044461A2/en
Publication of CA2255540A1 publication Critical patent/CA2255540A1/en
Application granted granted Critical
Publication of CA2255540C publication Critical patent/CA2255540C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence.
Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.
CA002255540A 1996-05-22 1997-05-22 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers Expired - Fee Related CA2255540C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65744996A 1996-05-22 1996-05-22
US08/657,449 1996-05-22
PCT/US1997/008962 WO1997044461A2 (en) 1996-05-22 1997-05-22 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Publications (2)

Publication Number Publication Date
CA2255540A1 true CA2255540A1 (en) 1997-11-27
CA2255540C CA2255540C (en) 2007-05-15

Family

ID=38069045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255540A Expired - Fee Related CA2255540C (en) 1996-05-22 1997-05-22 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Country Status (1)

Country Link
CA (1) CA2255540C (en)

Also Published As

Publication number Publication date
CA2255540C (en) 2007-05-15

Similar Documents

Publication Publication Date Title
WO1997044461A3 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
Novogrodsky et al. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors
WO1999002545A3 (en) Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
NO913211L (en) NEW MONOCLONAL ANTIBODY AGAINST NEW ANTIGEN ANNOUNCED TO HUMAN TUMORS.
HUP0500345A2 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MXPA02000192A (en) Compositions and methods for the therapy and diagnosis of lung cancer.
RU94028282A (en) Biospecific antibody, method of its preparing, monoclonal antibodies, pharmaceutical preparation, pharmaceutical sets, method of tumor cell removal, use of biospecific antibody fragment
AU2739188A (en) Novel antibodies
EP2196474A3 (en) Therapeutic targets in cancer
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
NZ331978A (en) Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system
BR0008161A (en) Use of a therapeutic composition for treating a tumor cell, therapeutic composition, and kit for treating a tumor cell
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
CA2579523A1 (en) Atad3a-binding molecules for treatment, detection and prevention of cancer
GB2278357B (en) Humanised antibodies directed against A33 antigen
HINODA et al. Detection of circulating adenocarcinoma-associated antigen in the sera of cancer patients with a monoclonal antibody
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
CA2255540A1 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO1994011508A3 (en) Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
WO1991017187A3 (en) A 35kd tumor associated protein antigen: uses and methods of detection
Wust et al. Antibody-dependent cytolysis of the human leukemia cell line K-562 in the absence of effector cells or complement
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
Ditzel et al. Tumour localization and pharmacokinetics of iodine-125 human monoclonal IgM antibody (COU-1) and its monomeric and half-monomeric fragments analysed in nude mice grafted with human tumour
Kawaharada et al. Studies on the CEA-like substance in gastric juice
Oltrogge et al. How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150522